Atopic dermatitis: dupilumab efficacy confirmed in real-world study

  • Wang C & al.
  • Int J Dermatol
  • 8 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab (Dupixent) is associated with clinical improvement and is well tolerated in real-world patients with moderate to severe atopic dermatitis (AD).

Why this matters

  • Real-world data are needed to confirm evidence from clinical trials.

Key results

  • Dupilumab was associated with improved clinical disease severity in 86% of patients.
    • 30% experienced complete clearance.
    • 56% experienced partial but stable improvement.
  • 95% of patients receiving dupilumab also used topical or systemic medications during their treatment.
  • 26% of patients treated with dupilumab experienced adverse events.
    • None were serious adverse events.
  • The most common adverse effects were dry eyes, conjunctivitis, and keratitis.
  • The most common reasons for discontinuation were adverse events and no/minimal improvement in disease activity.

Study design

  • 77 patients with AD treated with dupilumab were included.
  • Funding: None.

Limitations

  • Retrospective study.
  • Small patient sample size.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit